Vnitr Lek 2011, 57(12):1025-1028

Keratin fragments as a serological indicator in patients with a liver disease

J. Lata1,*, H. Mrlianová2, O. Stibůrek2, J. Nožička3, Z. Čermáková4, J. Gottwaldová4, P. Drozd5
1 Interní klinika Lékařské fakulty Ostravské univerzity a FN Ostrava, přednosta doc. MUDr. Arnošt Martínek, CSc.
2 Interní gastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Aleš Hep, CSc.
3 Histologická laboratoř Ústí nad Orlicí, přednosta primář MUDr. Jan Nožička, Ph.D.
4 Oddělení klinické biochemie FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Milan Dastych, CSc., MBA
5 Katedra biologie a ekologie Přírodovědecké fakulty Ostravské univerzity v Ostravě, vedoucí katedry Mgr. Pavel Drozd, Ph.D.

Introduction:
Determination of M30 antigen appears to be a sensitive method for evaluation of hepatocyte apoptosis. The aim of the present project was to implement this technique, compare M30 values in patients with a liver disease and healthy controls and to identify potential relationships between M30 values and other parameters.

Methods:
M30 antigen was assessed in 25 patients with a liver disease and 30 healthy controls. These results were compared between patients with a liver disease and the controls and correlated to a range of clinical and laboratory values, including tissue polypeptide-specific antigen (TPS), in patients with a liver disease.

Results:
We found significant differences in M30 values between controls and patients with a liver disease. The only significant correlations were the correlation between M30 and ALT, highly significant correlation between M30 and AST and highly significant correlation between M30 and TPS.

Conclusion:
The M30 antigen is a sensitive indicator of liver damage. Considering the highly significant correlation with TPS, it can be assumed that in some liver diseases, TPS could serve as a clinically useful indicator of apoptosis.

Keywords: liver disease; M30 antigen; tissue polypeptide-specific antigen (TPS); keratin fragments; hepatocyte apoptosis

Received: October 10, 2011; Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lata J, Mrlianová H, Stibůrek O, Nožička J, Čermáková Z, Gottwaldová J, Drozd P. Keratin fragments as a serological indicator in patients with a liver disease. Vnitr Lek. 2011;57(12):1025-1028.
Download citation

References

  1. R Development Core Team (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna: Austria 2011. www.R-project.org.
  2. Hůlek P, Dresslerová I. Steatóza a steatohepatitida u diabetika. Vnitř Lék 2011; 57: 364-367. Go to PubMed...
  3. Brůha R. Nealkoholová steatóza a steatohepatitida. Vnitř Lék 2010; 56: 173-175. Go to PubMed...
  4. Naveau S, Gaudé G, Asnacios A et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105. Go to original source... Go to PubMed...
  5. Tajmer P. Fibróza jater. In: Špičák J (ed.). Novinky v gastroenterologii a hepatologii. 1. vyd. Praha: Grada 2008: 35-46.
  6. Moll R, Franke WW, Schiller DL et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24. Go to original source... Go to PubMed...
  7. Fuchs E, Tyner AL, Guidice G et al. The human keratin genes and their differential expression. In: Sawyer RH (ed.). The Molecular and Developmental Biology of Keratins. New York: Academic Press 1987: 5-34. Go to original source...
  8. Sundström BE, D'Amico Y, Brundell J. Development of a new Profiligen TPA IRMA assay using monoclonal anti-cytokeratin antibodies. Int J Biol Markers 1995; 10: 166-173. Go to original source...
  9. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 2005; 59 (Suppl 2): S359-S362. Go to original source... Go to PubMed...
  10. Feldstein AE, Wieckowska A, Lopez AR et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078. Go to original source... Go to PubMed...
  11. Yilmaz Y, Dolar E, Ulukaya E et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844. Go to original source... Go to PubMed...
  12. Younossi ZM, Jarrar M, Nugent C et al. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). Obes Surg 2008; 11: 1430-1437. Go to original source... Go to PubMed...
  13. Zetterberg A, Skern T, Schoberl E et al. Molecular characterization of TPS (Abstract). 22nd Meeting. Groningen: ISOBM 1994: 354.
  14. Bremer K, Eklund G, Björklund B. Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer. Anticancer Res 1996; 16: 905-909.
  15. Glimelius B, Hoffman K, Einarsson R et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using tissue polypeptide specific antigen (TPS) measurements. Acta Oncol 1996; 35: 141-148. Go to original source... Go to PubMed...
  16. Klečka J, Pikner R, Toufarová P et al. Cytpkeratiny TPA, TPS, CYFRA 21-1 a UBC v séru a moči jako možné nádorové markery karcinomu močového měchýře. Ces Urol 2001; 1: 32-36.
  17. http://www.cskb.cz/res/file/doporuceni/TM/TM_tab3.pdf.
  18. Gonzalez-Quintela A, Abdulkader I, Campos J et al. Serum Levels of Keratin-18 Fragments (Tissue Polypeptide-Specific Antigen TPS) Are Correlated with Hepatocyte Apoptosis in Alcoholic Hepatitis. Dig Dis Sci 2009; 54: 648-653. Go to original source... Go to PubMed...
  19. Gonzalez-Quintela A, Abdulkader I, Otero E et al. Relationship between serum concentrations of keratin-18 and apoptosis in chronic hepatitis C. Clin Chem Lab Med 2010; 48: 897-899. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.